Tibolone inhibits leukocyte adhesion molecule expression in human endothelial cells

Molecular and Cellular Endocrinology

Volumn 162, Issue 1-2, 2000, Pages 87-94

  Simoncini, T ^a,b   Genazzani, A R ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Scuola Superiore di Studi   (Italy)

Author keywords

Atherosclerosis; Endothelial cells; Endothelial leukocyte adhesion molecules; Hormone replacement therapy; Tibolone

Indexed keywords

3ALPHA HYDROXY TIBOLONE; 3BETA HYDROXY TIBOLONE; DRUG METABOLITE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR; FULVESTRANT; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; TIBOLONE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL SURFACE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME IMMUNOASSAY; ESTROGEN ACTIVITY; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; NORTHERN BLOTTING; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR ENDOTHELIUM;

ARTERIOSCLEROSIS; CELL ADHESION MOLECULES; CELLS, CULTURED; E-SELECTIN; ENDOTHELIUM, VASCULAR; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN REPLACEMENT THERAPY; FEMALE; GENE EXPRESSION; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LEUKOCYTES; LIPOPOLYSACCHARIDES; NORPREGNENES; RNA, MESSENGER; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0034712815     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(00)00206-9     Document Type: Article

References (33)

1. Adams, D.H., Shaw, S., 1994. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet 343, 832-836.
2. Akishita M., Kozaki K., Eto M., Yoshizumi M., Ishikawa M., Toba K., Orimo H., Ouchi Y. Estrogen attenuates endothelin-1 production by bovine endothelial cells via estrogen receptor. Biochem. Biophys. Res. Commun. 251:1998;17-21.
3. Bourassa P.A., Milos P.M., Gaynor B.J., Breslow J.L., Aiello R.J. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. USA. 93:1996;10022-10027.
4. Castelo-Branco C., Casals E., Figueras F., Sanjuan A., Vicente J.J., Balasch J., Vanrell J.A. Two-year prospective and comparative study on the effects of tibolone on lipid pattern, behavior of apolipoproteins AI and B. Menopause. 6:1999;92-97.
5. Caulin-Glaser T., Watson C.A., Pardi R., Bender J.R. Effects of 17β-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J. Clin. Invest. 98:1996;36-42.
6. 2+ mobilization. Circ. Res. 81:1997;885-892.
7. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1986;156-159.
8. Collins T., Read M.A., Neish A.S., Whitley M.Z., Thanos D., Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB. J. 9:1995;899-909.
9. Cybulsky M., Gimbrone M.J. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 251:1991;788-791.
10. Farhat M.Y., Lavigne M.C., Ramwell P.W. The vascular protective effects of estrogen. Faseb. J. 10:1996;615-624.
11. Farish E., Barnes J.F., Fletcher C.D., Ekevall K., Calder A., Hart D.M. Effects of tibolone on serum lipoprotein and apolipoprotein levels compared with a cyclical estrogen/progestogen regimen. Menopause. 6:1999;98-104.
12. Genazzani A.R., Benedek-Jaszmann L.J., Hart D.M., Andolsek L., Kicovic P.M., Tax L. Org OD 14 and the endometrium. Maturitas. 13:1991;243-251.
13. Gimbrone M.A. Jr Vascular endothelium: an integrator of pathophysiologic stimuli in atherosclerosis. Am. J. Cardiol. 75:1995;67B-70B.
14. Grodstein F., Stampfer M., Manson J., Coditz G., Willett W., Rosner B., Speizer F., Hennekens C. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N. Engl. J. Med. 335:1996;453-461.
15. Grodstein F., Stampfer M.J., Colditz G.A., Willett W.C., Manson J.E., Joffe M., Rosner B., Fuchs C., Hankinson S.E., Hunter D.J., Hennekens C.H., Speizer F.E. Postmenopausal hormone therapy and mortality. N. Engl. J. Med. 336:1997;1769-1775.
16. Haenggi W., Bersinger N.A., Mueller M.D., Birkhaeuser M.H. Decrease of serum endothelin levels with postmenopausal hormone replacement therapy or tibolone. Gynecol. Endocrinol. 13:1999;202-205.
17. Koh K.K., Mincemoyer R., Bui M.N., Csako G., Pucino F., Guetta V., Waclawiw M., Cannon R.O. 3rd Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N. Engl. J. Med. 336:1997;683-690.
18. Lieberman E.H., Gerhard M.D., Uehata A., Walsh B.W., Selwyn A.P., Ganz P., Yeung A.C., Creager M.A. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann. Intern. Med. 121:1994;936-941.
19. Lloyd G.W., Patel N.R., McGing E.A., Cooper A.F., Kamalvand K., Jackson G. Acute effects of hormone replacement with tibolone on myocardial ischaemia in women with angina. Int. J. Clin. Pract. 52:1998;155-157.
20. Markiewicz, L.,Gurpide, E., 1990. In vitro evaluation of estrogenic, estrogen antagonistic and progestagenic effects of a steroidal drug (ORG. OD 14). J. Steroid Biochem. 535-541.
21. Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. N. Engl. J. Med. 340:1999;1801-1811.
22. Nabulsi A.A., Folsom A.R., White A., Patsch W., Heiss G., Wu K.K., Szklo M. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N. Engl. J. Med. 328:1993;1069-1075.
23. Pavlov P.W., Ginsburg J., Kicovic P.M., van der Schaaf D.B., Prelevic G., Coelingh Bennink H.J.T. Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures. Gynecol. Endocrinol. 13:1999;230-237.
24. Pervin S., Singh R., Rosenfeld M.E., Navab M., Chaudhuri G., Nathan L. Estradiol suppresses MCP-1 expression in vivo: implications for atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 18:1998;1575-1582.
25. Prelevic G.M., Beljic T., Ginsburg J. The effect of tibolone on cardiac flow in postmenopausal women with non-insulin dependent diabetes mellitus. Maturitas. 27:1997;85-90.
26. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340:1999;115-126.
27. Simoncini T., De Caterina R., Genazzani A.R. Selective estrogen receptor modulators: different actions on vascular cell adhesion molecule-1 (VCAM-1) expression in human endothelial cells. J. Clin. Endocrinol. Metab. 84:1999;815-818.
28. Springer T. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 76:1994;301-314.
29. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J. Am. Med. Assoc. 273:1995;199-208.
30. Vane, J.R., Anggard, E.E., Botting, R.M., 1990. Regulatory functions of the vascular endothelium. N. Engl. J. Med. 323, 27-35.
31. Wahl P., Walden C., Knopp R., Hoover J., Wallace R., Heiss G., Rifkind B. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N. Engl. J. Med. 308:1983;862-867.
32. Williams J.K., Adams M.R., Klopfenstein H.S. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation. 81:1990;1680-1687.
33. Zandberg P., Peters J.L., Demacker P.N., Smit M.J., de Reeder E.G., Meuleman D.G. Tibolone prevents atherosclerotic lesion formation in cholesterol-fed, ovariectomized rabbits. Arterioscler. Thromb. Vasc. Biol. 18:1998;1844-1854.